Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]
Titel:
Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]
Auteur:
Chau, Ian Peck-Radosavljevic, Markus Borg, Christophe Malfertheiner, Peter Seitz, Jean Francois Park, Joon Oh Ryoo, Baek-Yeol Yen, Chia-Jui Kudo, Masatoshi Poon, Ronnie Pastorelli, Davide Blanc, Jean-Frederic Chung, Hyun Cheol Baron, Ari D. Okusaka, Takuji Bowman, L. Cui, Zhanglin Lin Girvan, Allicia C. Abada, Paolo B. Yang, Ling Zhu, Andrew X.